I, too, thank you for the well-modeled analyses. Whenever I want to post material that the YH message board bans - things like charts, web links, or quoted material - I post over on the NVDQ board at Investor Village. I have a considerable number of links to studies over there.
(We'll see if the YH algorithms trap this!)
An observation put forth by Sir John Eric Erickson,
Surgeon – Extraordinary to Queen Victoria, 1873
There cannot always be fresh fields of conquest by the knife, there must be portions of the human frame that will ever remain sacred from its intrusions, at least in the surgeon's hands. That we have already, if not quite, reached these final limits, there can be little question. The abdomen, the chest, and the brain will be forever shut from the intrusion of the wise and humane surgeon.
I am curious how you assigned a number to one of the variables in your model. You expect Partnered / International Revenue will grow 3% q-o-q (~12.5% annualized). This sounds about right for the Intuitive piece of it and consequently a good number short term, but a little light for the remainder of the partnered capital items (SPY, Pinpoint, Luna) later on. Comments?
No mention of Firefly or Novadaq. However, nearly the first comments from Gary were about procedure growth areas. He highlighted two, hernia repair and colorectal resection. The latter benefits Novadaq greatly.
So, what happened two months ago? - Horrible Q1 results were released with an EPS surprise of -122%; a powerful incentive to short. As a result share price dropped hard but is now right back to where it was before the release, even in the face of continued heavy shorting. On the other side of every short bet, someone called and raised.
However, given the overoptimistic slant of management over the past year, I suspect the next quarter sales will hit GSA's inconclusive range and the share price will bounce around for another quarter.
Realistically, even if the repeal clears the house and senate, do you believe Mr. Obama would sign it? As it stands, the Affordable Care Act is his central legacy piece. Even a modest change would likely be seen by him as an unraveling thread.
Yes. And you forgot to mention the 19th century mustache over the "o". Probably an html hiccup (or maybe headquarters is moving to SE Asia).
If the lack of price movement of MDT, JNJ, SYK, and ISRG is an indicator, the repeal of the medical device tax is probably not reason for the jump. I vote for positive channel checks.
Available from sec.gov - NVDQ - Form 13G. Also search terms from headline, Why Primecap Management Co Just Disclosed Huge New Novadaq Technologies Inc Stake.